Standout Papers

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Respons... 2009 2026 2014 2020 2.3k
  1. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (2009)
    Jedd D. Wolchok, Axel Hoos et al. Clinical Cancer Research
  2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma (2015)
    Dirk Schadendorf, F. Stephen Hodi et al. Journal of Clinical Oncology
  3. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (2017)
    Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology
  4. RECIST 1.1—Update and clarification: From the RECIST committee (2016)
    Lawrence H. Schwartz, Saskia Litière et al. European Journal of Cancer
  5. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (2017)
    Antoni Ribas, Reinhard Dummer et al. Cell
  6. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial (2018)
    F. Stephen Hodi, Vanna Chiarion‐Sileni et al. The Lancet Oncology
  7. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma (2017)
    Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology
  8. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial (2012)
    Kim Margolin, Marc S. Ernstoff et al. The Lancet Oncology
  9. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients (2003)
    F. Stephen Hodi, Martín C. Mihm et al. Proceedings of the National Academy of Sciences
  10. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens (2017)
    Romualdo Barroso‐Sousa, William T. Barry et al. JAMA Oncology
  11. Monitoring immune-checkpoint blockade: response evaluation and biomarker development (2017)
    Mizuki Nishino, Nikhil H. Ramaiya et al. Nature Reviews Clinical Oncology
  12. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019)
    Omid Hamid, Caroline Robert et al. Annals of Oncology
  13. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013)
    Patrick A. Ott, F. Stephen Hodi et al. Clinical Cancer Research
  14. Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer (2016)
    Mizuki Nishino, Anita Giobbie‐Hurder et al. JAMA Oncology
  15. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients (2008)
    F. Stephen Hodi, Marcus O. Butler et al. Proceedings of the National Academy of Sciences
  16. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 (2012)
    Daniel S. Chen, Bryan Irving et al. Clinical Cancer Research
  17. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors (2016)
    Frank B. Cortazar, Kristen A. Marrone et al. Kidney International
  18. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma (2018)
    Scott J. Rodig, Daniel Gusenleitner et al. Science Translational Medicine
  19. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019)
    Suzanne L. Topalian, F. Stephen Hodi et al. JAMA Oncology
  20. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy (2016)
    Lucie Heinzerling, Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
  21. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (2017)
    Guillermo de Velasco, Youjin Je et al. Cancer Immunology Research
  22. The Intersection between Tumor Angiogenesis and Immune Suppression (2019)
    Osama E. Rahma, F. Stephen Hodi Clinical Cancer Research
  23. PD-1 Inhibitor–Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course (2016)
    Mizuki Nishino, Nikhil H. Ramaiya et al. Clinical Cancer Research
  24. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints (2018)
    Lee‐Shing Chang, Romualdo Barroso‐Sousa et al. Endocrine Reviews
  25. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy (2020)
    Adrienne Luoma, Shengbao Suo et al. Cell
  26. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016)
    Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research
  27. Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors (2021)
    Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research
  28. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (2013)
    Jedd D. Wolchok, F. Stephen Hodi et al. Annals of the New York Academy of Sciences
  29. Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas (2021)
    Funda Meric‐Bernstam, Randy F. Sweis et al. Clinical Cancer Research

Immediate Impact

74 by Nobel laureates 32 from Science/Nature 294 standout
Sub-graph 1 of 13

Citing Papers

STING-induced regulatory B cells compromise NK function in cancer immunity
2022 StandoutNature
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
2021 StandoutNature
5 intermediate papers

Works of F. Stephen Hodi being referenced

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
2017 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
and 12 more

Author Peers

Author Last Decade Papers Cites
F. Stephen Hodi 33441 16392 10242 509 42.8k
Lieping Chen 33760 35531 9061 366 54.6k
Suzanne L. Topalian 32079 26635 12249 211 48.3k
Jedd D. Wolchok 44357 29224 15851 558 63.2k
Michael B. Atkins 24830 11813 15717 570 39.8k
Charles G. Drake 18236 15755 5968 483 39.2k
John M. Kirkwood 30784 18585 17591 679 45.4k
Julie R. Brahmer 28602 7419 7584 349 37.4k
Antoni Ribas 38917 22192 26896 548 59.5k
Catherine Sautès‐Fridman 14429 15615 8164 300 28.2k
Markus Wallwiener 19886 9139 7745 273 30.4k

All Works

Loading papers...

Rankless by CCL
2026